SVRA logo

SVRA
Savara Inc

22,716
Mkt Cap
$1.17B
Volume
575.00
52W High
$7.01
52W Low
$1.89
PE Ratio
-10.76
SVRA Fundamentals
Price
$5.76
Prev Close
$5.77
Open
$5.67
50D MA
$5.43
Beta
1.06
Avg. Volume
3.8M
EPS (Annual)
-$0.4838
P/B
10.55
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
PANTHERx Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI*
PANTHERx Rare Pharmacy, the trusted leader and innovator in patient access and support services for personalized rare disease care, and Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical...
Business Wire·17h ago
News Placeholder
More News
News Placeholder
Savara (NASDAQ:SVRA) Shares Down 5.1% - Should You Sell?
Savara (NASDAQ:SVRA) Trading Down 5.1% - What's Next...
MarketBeat·10d ago
News Placeholder
Savara Inc. (NASDAQ:SVRA) Short Interest Up 33.1% in December
Savara Inc. (NASDAQ:SVRA - Get Free Report) saw a large increase in short interest in December. As of December 15th, there was short interest totaling 20,185,493 shares, an increase of 33.1% from the...
MarketBeat·10d ago
News Placeholder
Swedbank AB Takes $1.96 Million Position in Savara Inc. $SVRA
Swedbank AB acquired a new stake in Savara Inc. (NASDAQ:SVRA - Free Report) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor...
MarketBeat·12d ago
News Placeholder
What is HC Wainwright's Forecast for Savara FY2027 Earnings?
Savara Inc. (NASDAQ:SVRA - Free Report) - Investment analysts at HC Wainwright upped their FY2027 earnings per share (EPS) estimates for shares of Savara in a research note issued on Tuesday...
MarketBeat·15d ago
News Placeholder
FY2029 Earnings Estimate for Savara Issued By HC Wainwright
Savara Inc. (NASDAQ:SVRA - Free Report) - Stock analysts at HC Wainwright increased their FY2029 earnings per share (EPS) estimates for shares of Savara in a note issued to investors on Tuesday...
MarketBeat·16d ago
News Placeholder
Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced today that it has resubmitted the MOLBREEVI BLA to the FDA, with...
Business Wire·18d ago
News Placeholder
Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management team will present and host...
Business Wire·23d ago
News Placeholder
Savara Inc. (NASDAQ:SVRA) Receives Average Rating of "Moderate Buy" from Brokerages
Shares of Savara Inc. (NASDAQ:SVRA - Get Free Report) have received an average recommendation of "Moderate Buy" from the ten brokerages that are currently covering the company, Marketbeat.com...
MarketBeat·23d ago
News Placeholder
Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI*
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the EPO notified the Company of its intention to grant a...
Business Wire·29d ago
<
1
2
...
>

Latest SVRA News

View

Advertisement|Remove ads.

Advertisement|Remove ads.